Novavax, Inc [NASDAQ: NVAX] stock went on a downward path that fall over -0.30% on Tuesday, amounting to a one-week price decrease of less than -3.99%.
Over the last 12 months, NVAX stock dropped by -16.29%. The one-year Novavax, Inc stock forecast points to a potential upside of 48.78. The average equity rating for NVAX stock is currently 2.71, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.09 billion, with 161.96 million shares outstanding and 147.56 million shares in the current float. Compared to the average trading volume of 8.11M shares, NVAX stock reached a trading volume of 7129330 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Novavax, Inc [NVAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $13.14 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.71. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Novavax, Inc shares, keeping their opinion on the stock as Sell, with their previous recommendation back on June 17, 2025. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on February 28, 2025, representing the official price target for Novavax, Inc stock. Previously, the target price had yet another raise to $8, while JP Morgan analysts kept a Underweight rating on NVAX stock.
NVAX Stock Performance Analysis:
Novavax, Inc [NVAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.99. With this latest performance, NVAX shares gained by 1.82% in over the last four-week period, additionally sinking by -20.17% over the last 6 months – not to mention a drop of -16.29% in the past year of trading.
Insight into Novavax, Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Novavax, Inc [NVAX] shares currently have an operating margin of 33.69% and a Gross Margin at 87.18%. Novavax, Inc’s Net Margin is presently recorded at 38.14%.
Novavax, Inc (NVAX) Capital Structure & Debt Analysis
Novavax, Inc (NVAX) Efficiency & Liquidity Metrics
Novavax, Inc (NVAX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Novavax, Inc. (NVAX) effectively leverages its workforce, generating an average of $502836.13 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.06% and a Quick Ratio of 2.03%, indicating strong ability to cover short-term liabilities.
NVAX Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novavax, Inc go to 37.02%.
Novavax, Inc [NVAX] Institutonal Ownership Details
There are presently around $57.90%, or 63.47% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 14.08 million shares, which is approximately 9.4861%. BLACKROCK INC., holding 11.85 million shares of the stock with an approximate value of $$149.98 million in NVAX stocks shares; and BLACKROCK INC., currently with $$122.32 million in NVAX stock with ownership which is approximately 6.5118%.
